Propanc Advances PRP After Strong Preclinical Pancreatic Cancer Results
Melbourne, Australia – August 27, 2026 Propanc Biopharma announced new preclinical and early translational data for PRP in pancreatic...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Melbourne, Australia – August 27, 2026 Propanc Biopharma announced new preclinical and early translational data for PRP in pancreatic...
Irving, Texas, United States, Aug 27, 2026 Caris Life Sciences has announced the publication of a study in npj...
Ramat Gan, Israel — August 17, 2026 Can-Fite BioPharma Ltd. announced new preclinical findings showing that namodenoson enhanced the...
ROCKVILLE, Md., August 6, 2026 Theriva Biologics announced that the first patient has been dosed in the VIRAGE2 Phase...
BOSTON, June 17, 2026 Verastem Oncology announced positive updated safety and efficacy findings from the Phase 1b/2a RAMP 205...
